XSHE
300562
Market cap476mUSD
Oct 09, Last price
15.05CNY
1D
3.15%
1Q
2.52%
Jan 2017
-47.97%
IPO
94.51%
Name
Guangdong Transtek Medical Electronics Co Ltd
Chart & performance
P/E
40.12
P/S
3.34
EPS
0.38
Div yield, %
1.92%
Shrs. gr., 5y
-0.37%
Rev. gr., 5y
-11.54%
Revenues
986m
+0.23%
Net income
82m
+33.63%
CFO
153m
+28.62%
Dividend
Oct 15, 20260.13 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Guangdong Transtek Medical Electronics Co., Ltd, established in Zhongshan, China, in 2002, specializes in the development, manufacturing, and sale of various health-focused technological products within the Chinese market. The company provides a comprehensive range of offerings, including medically certified devices, internet-connected healthcare solutions, and smart wearable technology. Their product catalog features equipment for remote patient observation, blood pressure measurement tools, digital weighing scales, versatile wearable gadgets, and wireless audio devices.
Key people
Rong Wu
Chief Financial Officer · since 2025
Wei Li
Deputy General Manager, Secretary of the Board · since 2025
Qiguang Liang
Deputy General Manager
Huahai Sha
Deputy General Manager, Director · since 2012
Weidong Wan
Deputy General Manager
Jiongzhang Mai
Director · since 2021
Zhigang Pan
President, Director · since 2023
Weichao Pan
Chairman of the Board, General Manager · since 2022
Independent Director
Xingguo Xu
Independent Director · since 2024
Guozheng Yu
Independent Director
Xiaodong Zou
Independent Director
Headquarters & legal address
火炬开发区东利路105号
中山市, GD 528400
CN
中山市, GD 528400
CN
Address
donglilu105
Zhongshan, GD 528400
CN
Zhongshan, GD 528400
CN
Other language
Guangdong Transtek Medical Electronics Co.,Ltd
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||